Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

PHN is operationally defined as pain that persists ... Immunocompromised patients might require longer periods of treatment. Treatment should be discontinued if both VZV DNA and anti-VZV antibody ...

Many Brits might unknowingly be walking a knife’s edge with their health, as an expert warned if left untreated, the disease ...

Summary: Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is ...

Many Brits could be unknowingly teetering on the brink of serious health issues, as a leading expert warns that if left ...

Treatment details: Time to treatment after onset ... developed PHI and patients with self-reported continued pain were considered to have developed PHN. The NRS score was assessed on the 1st day of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...